Trial Profile
A retrospective study evaluating benefits of switching to raltegravir-containing regimens in the HIV+ older population.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms RAL-AGE
- 30 Dec 2016 New trial record